Literature DB >> 9169683

Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results.

G J Jager1, E T Ruijter, C A van de Kaa, J J de la Rosette, G O Oosterhof, J R Thornbury, S H Ruijs, J O Barentsz.   

Abstract

PURPOSE: To assess whether a TurboFLASH (fast low-angle shot) magnetic resonance (MR) sequence can improve the accuracy of fast spin-echo (SE) endorectal coil MR imaging in the staging and localization of prostate cancer.
MATERIALS AND METHODS: In 57 patients with prostate cancer, MR imaging was performed with the following sequences: T1-weighted SE, T2-weighted fast SE, single-section gadolinium-enhanced dynamic subtracted TurboFLASH (one image every 1.25 or 2.5 seconds), and late-phase gadolinium-enhanced T1-weighted SE. Retrospectively, two blinded independent readers graded onset and steepest slope of enhancement and assessed tumor involvement and capsular penetration. MR findings were correlated with histopathologic results.
RESULTS: On TurboFLASH images, prostate cancer was characterized by early and rapidly accelerating enhancement compared with that of surrounding tissues. Average sensitivity, specificity, and accuracy for detection of tumor involvement for the two readers with TurboFLASH images were 73.5%, 81.0%, and 77.5%. These values with fast SE images were 57.5%, 80.5%, and 72.0%. Depiction of capsular penetration and delineation and staging of tumor were better when TurboFLASH images were included with fast SE images. Differences between the two sequences, however, were not statistically significant.
CONCLUSION: Because the TurboFLASH sequence did not statistically significantly improve tumor localization and staging results, routine use is not recommended. The technique may be useful for selected patients with equivocal evidence of capsular penetration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169683     DOI: 10.1148/radiology.203.3.9169683

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  46 in total

1.  Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.

Authors:  B Nicolas Bloch; Elizabeth M Genega; Daniel N Costa; Ivan Pedrosa; Martin P Smith; Herbert Y Kressel; Long Ngo; Martin G Sanda; William C Dewolf; Neil M Rofsky
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

Review 2.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.

Authors:  J Kurhanewicz; D B Vigneron; S J Nelson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

3.  Dynamic contrast-enhanced MRI of the prostate: is this the way to proceed for characterization of prostatic carcinoma?

Authors:  R H Oyen
Journal:  Eur Radiol       Date:  2003-05       Impact factor: 5.315

Review 4.  Methods for volume assessment of prostate cancer.

Authors:  Heinz-Peter Schlemmer; Stefan Corvin
Journal:  Eur Radiol       Date:  2004-02-06       Impact factor: 5.315

5.  [Standardised scoring of a multi-parametric 3-T MRI for a targeted MRI-guided prostate biopsy].

Authors:  C Arsov; D Blondin; R Rabenalt; G Antoch; P Albers; M Quentin
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

6.  The role of magnetic resonance imaging in oncology.

Authors:  Concepción González Hernando; Laura Esteban; Teresa Cañas; Enrique Van den Brule; Miguel Pastrana
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

Review 7.  Prostate MR imaging at high-field strength: evolution or revolution?

Authors:  Olivier Rouvière; Robert P Hartman; Denis Lyonnet
Journal:  Eur Radiol       Date:  2005-09-10       Impact factor: 5.315

8.  Contrast-enhanced ultrasound imaging of prostate cancer.

Authors:  Ethan J Halpern
Journal:  Rev Urol       Date:  2006

Review 9.  Imaging tumour angiogenesis.

Authors:  Tony Jeswani; Anwar R Padhani
Journal:  Cancer Imaging       Date:  2005-12-01       Impact factor: 3.909

10.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.